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Recent genomic studies of sporadic clear cell renal cell carcinoma (ccRCC) have uncovered novel driver 
genes and pathways. Given the unequal incidence rates among men and women (male:female incidence 
ratio approaches 2:1), we compared the genome-wide distribution of the chromosomal abnormalities 
in both sexes. We observed a higher frequency for the somatic recurrent chromosomal copy number 
variations (CNVs) of autosomes in male subjects, whereas somatic loss of chromosome X was detected 
exclusively in female patients (17.1%). Furthermore, somatic loss of chromosome Y (LOY) was detected 
in about 40% of male subjects, while mosaic LOY was detected in DNA isolated from peripheral blood 
in 9.6% of them, and was the only recurrent CNV in constitutional DNA samples. LOY in constitutional 
DNA, but not in tumor DNA was associated with older age. Amongst Y-linked genes that were 
downregulated due to LOY, KDM5D and KDM6C epigenetic modifiers have functionally-similar X-linked 
homologs whose deficiency is involved in ccRCC progression. Our findings establish somatic LOY 
as a highly recurrent genetic defect in ccRCC that leads to downregulation of hitherto unsuspected 
epigenetic factors, and suggest that different mechanisms may underlie the somatic and mosaic LOY 
observed in tumors and peripheral blood, respectively.
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Chromosomal aneuploidy is a common phenomenon in many cancers, and the analysis of copy number varia-
tions (CNVs) across multiple samples has helped identify relevant driver genes for human cancers. For example, 
several oncogenes including MYC, EGFR, ERBB2 and CCND1 are recurrently amplified through chromosomal 
or focal gains, while multiple tumor suppressors such as ATM, PTEN and CDKN2A are commonly deleted in 
different cancers1.
Clear cell renal cell carcinoma (ccRCC), which accounts for 75–80% of all renal cell carcinomas, is charac-
terized by loss of chromosome 3p in about 90% of the sporadic cases2. Remarkably, 3p harbors the four most 
commonly mutated genes in ccRCC whose cancer-driving activities have been established in the disease; VHL3, 
PBRM14, SETD25, and BAP16, which are mutated in 80%, 40%, 19% and 12% of cases, respectively7–9. Inactivation 
of VHL leads to constitutive stabilization of the hypoxia inducible transcription factors (HIF), and abnormal 
activation of their downstream genes, which contribute to cancer development10. The remaining three genes 
encode proteins involved in chromatin remodeling and histone modifications, highlighting the important role of 
epigenome aberration in the disease2. While the incidence of ccRCC is increasing worldwide, the male-to-female 
incidence ratios are typically within the range of 1.5–2:1.011, arguing for a sex-specific analysis of the genomic 
abnormalities. Here, we set out to investigate the occurrence and the extent of germline and somatic CNVs in spo-
radic ccRCC in male and female patients separately, and to further characterize those affecting sex chromosomes.
Results and Discussion
Loss of chromosome Y is common in ccRCC. Using whole-genome sequencing (WGS) data of ccRCC 
and matched constitutional DNA sample pairs, which we have reported recently12, we interrogated CNVs in DNA 
from 52 male and 41 female patients (discovery set; Supplementary Table 1) by analyzing coverage of sequencing 
reads mapped to each chromosome (see Methods). In line with previous literature, the most frequent somatic 
CNV was the loss of 3p detected in 91% of samples, followed by recurrent gains of chromosomes 5q (32%), 7 
(23.6%), 12 (13%), and losses of chromosomes 14q (30%), 8p (29%) and 9 (16%). Overall, tumors from male 
patients exhibited higher prevalence for the recurrent chromosomal aberrations, in particular for gain of 7q 
(28% in males vs. 17% in females) and deletion of 9p (25% in males vs. 10% in females) (Fig. 1a). In contrast, we 
observed that loss of chromosome X (LOX) exclusively happens in female patients (17.1% of female cases). Given 
that several X-linked genes escape X-inactivation, and have therefore two functional copies in females but one 
in males, this observation suggests that presence of a copy of chromosome X may potentially be essential for the 
survival of cancer cells. Curiously, whereas no tumors from male patients displayed LOX, loss of chromosome Y 
(LOY) was the second most frequent somatic chromosome aneuploidy in these tumors (36.5% of male subjects, 
N = 19; Fig. 1a). The fraction of cells estimated to be affected by somatic LOY in these patients ranged from 11% 
to 75%, and in 14 patients somatic LOY was detected in at least 20% of the cells (Fig. 1b). Next, we examined the 
presence of CNVs in constitutional DNA isolated from peripheral samples collected from the same patients. Of 
significance, LOY was the only recurrent aneuploidy in constitutional DNA of our samples that was detected in 5 
male patients (9.6%; Supplementary Figure 1), of which 4 showed the deletion in more than 20% of cells (Fig. 1b). 
Corroborating previous studies13,14, the observed LOY was associated with older age in patients (P = 0.04); the 
average age of patients with LOY in the peripheral blood was 68.9 year in comparison to 58.8 year in those with-
out this abnormality. Notably, we did not observe any association between age of patients and extent of somatic 
LOY in tumors of the affected patients.
LOY is a whole-chromosome event. Given the high prevalence of LOY in tumors and peripheral DNA 
of male patients, we further analyzed LOY in our sample series, particularly whether the observed LOY spans the 
whole chromosome or is focal. Analysis of sequencing read coverage along chromosome Y showed that the loss 
is observed throughout the chromosome in samples affected by LOY (Fig. 2a), suggesting that the deletion affects 
the whole chromosome. Based on availability of DNA, we subjected samples from seven of the patients affected 
with somatic LOY to verification by an orthogonal Y-Chromosome deletion detection assay surveying the pres-
ence of twenty specific regions of the Y chromosome by polymerase chain reaction (PCR) (see Methods). Somatic 
LOY at the chromosomal level was confirmed in all examined tumors, evident from an attenuated amplification 
of Y-chromosome-specific loci in DNA isolated from tumor samples compared to that of the matched constitu-
tional DNA. This pattern was not observed in samples of other male patients who had not been identified as being 
affected by somatic LOY based on the analysis of their WGS data (Fig. 2b).
To confirm these findings, we screened tumor and matched control DNA sample pairs of an additional 
48 male ccRCC patients (validation set) for LOY using the above PCR-based assay. This analysis revealed 
somatic LOY in 20 (42.7%) of the validation sample set, demonstrating that this is a common genomic aber-
ration in ccRCC, detected in 39.6% overall (discovery and validation sets; n = 100) of male ccRCC patients 
(Supplementary Figure 2). Analysis of association between somatic LOY and clinical annotations including 
tumor stage or grade did not show any significant relationships.
LOY results in downregulation of epigenetic modifier genes. We further examined the possible 
effect of somatic LOY at the RNA level by interrogating a RNA-Seq dataset on gene expression in normal and 
tumor samples from male patients within the discovery set12. We found that 11 genes had significantly differ-
ent patterns of expression in tumors of the patients with and without somatic LOY (false-discovery rate (FDR) 
< 0.01; Supplementary Table 2). These 11 genes were located on chromosome Y, and while expressed in nor-
mal kidney tissue, exhibited lower expression in tumors of patients harboring somatic LOY, indicating that this 
aberration may have functional consequences through deregulation of the affected genes. Moreover, the level of 
expression of each gene was found to be inversely correlated to the proportion of cells affected by LOY (Fig. 3). 
This observation was confirmed using gene expression data generated by microarrays, which was available for 
29 tumors of the validation set15 (Supplementary Figure 3). We surveyed the list of genes affected for potential 
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functionally-relevant candidates. Among these genes, TMSB4Y has recently been identified as a tumor suppressor 
gene downregulated in male breast cancers16, but not connected to ccRCC. Likewise, deletion of KDM5D has 
been detected in 52% of prostate cancers17. KDM5D encodes a lysine-specific histone H3 demethylase, which 
plays an important role in epigenetic regulation18. Furthermore, it has been shown that knockdown of KDM5D 
through RNA-interference (RNAi) increases cell proliferation and reduces apoptosis in prostate cancer19, sug-
gesting a tumor suppressor function for this gene. Intriguingly, KDM5C, the X-linked homologue of KDM5D 
is recurrently mutated in ccRCC8,9,12, and its inactivation leads to genomic instability in ccRCC through dereg-
ulation of H3K4 methylation20. KDM5D shows 85% sequence identity to KDM5C, and the products of these 
two genes possess a similar function in demethylating tri-methyl H3K418,20. Given this functional similarity, we 
surveyed the mutational status of KDM5C in our discovery set, and investigated possible relationships between 
mutational status of KDM5C and KDM5D in tumors of male patients. In female patients, KDM5C was deleted in 
tumors of 7 cases through somatic LOX, and was affected by focal somatic deletions in two additional patients. 
Furthermore, somatic mutations of KDM5C were present in tumors of 3 patients who were also affected with 
LOX (P = 0.003, Fisher’s exact test, Supplementary Figure 4). Overall, KDM5C was affected with somatic genomic 
aberrations in 9 out of 41 (22%) female cases. As KDM5C escapes the X-inactivation21, the concomitant muta-
tions of KDM5C and LOX in the same tumors may suggest that this gene is a classical tumor suppressor affected 
with bi-allelic inactivation in ccRCC. In male cases, we identified KDM5C mutations in tumors of 3 patients 
(5.8%), of which one was also affected by somatic LOY (Supplementary Figure 4). We did not detect any mutation 
or a focal CNV affecting KDM5D in tumors of the male patients who did not exhibit LOY.
Our list of LOY-associated down-regulated genes (Supplementary Table 2) includes another epigenome modi-
fier with an X-linked homologue that is also recurrently mutated in ccRCC; UTY/KDM6C. KDM6C demethylates 
Figure 1. Copy number analysis in ccRCC. (a) Bar graphs show the frequency of copy number variations 
across the genome in ccRCC tumors. Frequencies are presented in samples from female and male cases 
separately. (b) Status of chromosome Y in DNA isolated from tumors (Y-axis) and patient-matched peripheral 
blood (X-axis) is shown for individual male subjects. In samples affected by LOY, the normalized coverage of 
chromosome Y, shown on Y and X axes for tumor and normal samples, respectively, is lower than the expected 
value of 0.5. The color codes define patient groups with different states for LOY.
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H3K27, a function similar to that of KDM6A22. These genes also share over 83% in sequence similarity, resulting 
in highly conserved active sites in their products. Mutations of KDM6A leading to its inactivation have been 
recurrently observed in ccRCC8,23, highlighting this gene as a potential key tumor suppressor in renal cancer. In 
addition to being affected by somatic LOX in 7 female patients, KDM6A was also affected by focal deletion in a 
female patient in our cohort.
KDM5D expression reduces viability of renal cancer cells. Given the reported tumor-suppressive 
function of KDM5D in prostate cancer19, and of its X-link homolog KDM5C in renal cancer20, we set out to exam-
ine whether KDM5D expression has an anti-tumor activity in renal cancer. We first evaluated KDM5D expres-
sion levels in several renal cancer cell lines, which have been derived from tumors resected from male patients. 
Amongst cell lines examined, ACHN cell line did not show any expression for KDM5D (Fig. 4a). This observation 
was in line with a previous study reporting the loss of chromosome Y in ACHN cell line24. We therefore selected 
this cell line for functional analysis of KDM5D expression. Ectopic expression of KDM5D cells reduced cell 
viability to 65% as compared to control transfection (Fig. 4b,c), suggesting the potential involvement of KDM5D 
depletion in renal cancer pathology.
Conclusions
Emerging data emphasizes an association between LOY in peripheral blood and higher risk of cancer25. Likewise 
focal or chromosome-level somatic LOY occurs recurrently in different malignancies; however, current knowl-
edge of mechanisms by which LOY may contribute to cancer is limited. Recent genomic studies of ccRCC have 
highlighted the importance of molecular aberrations that impair the function of chromatin remodeling and epi-
genetic modifiers in ccRCC development5,20,26–29. Our study expands these findings by highlighting the prevalence 
of somatic LOY among men affected by ccRCC, and suggesting a functional relevance for this aberration through 
down-regulation of previously unrecognized epigenetic modifiers KDM5D and KDM6C. Given the functional 
Figure 2. LOY affects whole chromosome. (a) Sequencing coverage across chromosome Y is shown in 
constitutional DNA samples without (top) and with LOY (middle), and in a tumor sample with LOY (bottom). 
(b) The cartoon on top depicts the location of the loci examined by PCR on Y chromosome. The dot graph on 
bottom shows average of relative amplification values (Tumor/normal samples of the same patient) for each 
locus in patients with (red) and without (blue) somatic LOY (SLOY). Error bars show the range across patients 
of each group.
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similarities between these genes and their X-linked homologs, it is plausible that down-regulation of KDM5D and 
KDM6C, through somatic LOY, may contribute to ccRCC development or progression. Our in vitro data shows 
that over expression of KDM5D in cancer cells that are affected by LOY reduces cell viability. These findings indi-
cate that down-regulation of KDM5D through LOY may contribute to the pathogenesis of renal cancer. However, 
further detailed analysis through future functional studies is warranted to understand the exact function and 
pathway context of KDM5D in renal cancer.
Methods
Patient samples and DNA isolation. Clinical information for patients included in this study is pre-
sented in Supplementary Table 1. Patients undergoing nephrectomy for suspected renal cancer during the period 
December 2008 to March 2011 at St James’s University Hospital in Leeds, UK; University Hospital Motol, Prague, 
Czech Republic; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Th. Burghele Hospital, Bucharest, 
Romania; and N. N. Blokhin Cancer Research Centre, Moscow, Russia, were recruited to the study after informed 
consent was obtained. Recruitment in Central and Eastern Europe was coordinated by the International Agency 
for Research on Cancer (IARC). All experiments and methods were performed in accordance to the ethics guide-
lines from the International Cancer Genome Consortium (ICGC) and to the relevant national regulations and 
with sampling and clinical data collection being undertaken according to predefined standard operating pro-
cedures (SOPs) based on guidelines from ICGC. Ethical approvals were obtained from the Leeds (East) Local 
Research Ethics Committee, the IARC Ethics Committee, as well as from local ethics committee for recruiting 
centers in Czech Republic, Romania, and Russia. DNA from fresh-frozen tumor tissue samples and buffy coat was 
isolated using Autopure (Qiagen) as described previously12, and were quantified by Quant-iT PicoGreen dsDNA 
Assay Kit (Invitrogen, ON, CAN).
Inference of LOY from WGS data. WGS data of tumor and blood DNA samples studied here were 
reported previously12. To detect aneuploidy and LOY from WGS data, we first measured read coverage across 
the genome in 5 Kbp bins. In each sample, the coverage was normalized by the median coverage across the 
autosomes. We then estimated, for each sample, the median normalized coverage in each chromosome arm. 
The only exception was chromosome Y which was considered as a whole. In order to avoid noise due to map-
pability issues, we used only the top 1000 bins with the lowest median divergence from the expected baseline in 
the normal samples. We used this normalized median coverage per chromosome arm to test aneuploidy in each 
sample. For each chromosome arm (or chromosome Y), a mixture of two Gaussian distributions was fitted to the 
empirical distribution of the median normalized coverage across samples. The main Gaussian was used as the 
Figure 3. Somatic LOY leads to downregulation of Y-linked genes. Expression of Y chromosome genes 
downregulated in patients affected by somatic LOY is compared to the proportion of cells estimated to harbor 
somatic LOY in individual tumor samples.
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null distribution (Supplementary Figure 5) to derive P-values. A chromosome arm was flagged as aneuploid if the 
Bonferonni-adjusted P-value was smaller than 0.01 and at least 10% of cells were affected. The proportion of cell 
with aneuploidy was estimated as the proportion of missing/excess coverage. For LOY, we expect a normalized 
coverage of 0.5 and the proportion of cells with LOY was (0.5-coverage)/0.5.
We used a logistic regression to test the association of LOY with age. Finally, the CNVs used for KDM5C or 
KDM6A deletion investigation were detected by PopSV30 using the normal samples as reference and 5 Kbp bins.
PCR-based detection of LOY. To examine the status of LOY in DNA of tumor and blood samples, Y 
Chromosome Deletion Detection System assay, Version 2 (Promega, WI, USA) was used as instructed by the 
manufacturer. Briefly, 20 specific regions of the Y chromosome were amplified by PCR using 5 multiplex master 
mixes, and PCR products were loaded on a QIAxcel instrument (Qiagen, ON, CAN). Densities of PCR products 
were estimated by BioCalculator software (v.3.2) and a normalization was performed by the control primer pair 
included in each multiplex master mix to control the amplification efficacy. We also included samples from three 
male subjects without LOY and one female sample to control the performance of the assay. Similar to the analysis 
on WGS data, the probes were first normalized by the median probe amplification value across the normal sam-
ples. Then the median of the normalized amplification was computed for each sample. It summarized the overall 
amplification of chromosome Y in each sample. These values were used to produce Supplementary Figure 2 and 
to identify LOY. Following the same analysis as for the WGS data, the mixture of Gaussian distributions was fitted 
on the normalized amplification of the normal samples. Samples which deviated significantly (P < 0.01) from the 
expected amplification and with an estimated proportion of affected of cells > 10% were flagged as being affected 
by LOY.
Gene expression analysis. Transcriptome profiles of the tumor samples included in this study (previously 
reported in our earlier publication12), were used to examine differential gene expression between male subjects 
affected with somatic LOY and those without this abnormality. RNA-seq data was available for tumors of 34 
patients, of which 21 had RNA-seq for matched normal kidney samples. Differentially expressed genes between 
tumors affected with somatic LOY and those without this abnormality were identified using Student’s T-Test on 
log2-transformed RPKM data, and the Benjamini-Hochberg method was used to correct multiple testing. Genes 
with a FDR< 0.01 were considered differentially expressed. A linear regression was used to test the association 
between the proportion of cells with somatic LOY and gene expression (RPKM).
Figure 4. Effect of KDM5D on viability of renal cancer cells. (a) Expression levels of KDM5D mRNA in 
renal cancer cell lines derived from tumors procured from male patients, as measured by qRT-PCR. GAPDH 
served as a housekeeping gene for measurement of relative gene expression. (b) Over expression of KDM5D 
in ACHN cell line reduces cell viability. Values are the mean ± SD of six independent experiments. **P < 0.01 
when compared to the corresponding results from control (ctrl) (Mann-Whitney U test). (c) Over expression of 
KDM5D following transfection was confirmed using qRT-PCR.
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Gene expression microarray data for 29 tumors of validation samples had previously been reported15, and 
were used to confirm the anti-correlation between the proportion of cells with somatic LOY and gene expression 
levels (log2 intensity).
Cell viability assay. Renal cancer cell lines 786-O, A704, Caki-2, ACHN were obtained from ATCC 
(Rockville, USA) and cultured in RPMI, EMEM and McCoy medium supplemented with 10% (v/v) fetal bovine 
serum (FBS), 100 U/ml penicillin and 100 lg/ml streptomycin. Cells were incubated at 37 °C and 5% (v/v) CO2. 
For viability assays, 5000 cells were transfected with 100 ng of either KDM5D cDNA-expressing (courtesy of Dr. 
Stephane Richard) or control empty vector (Sigma, Oakville, Canada) in 96-well plates using Lipofectamine 3000 
(Invitrogen) according to the manufacturer’s instructions. CellTiter-Glo assay (Promega, WI, USA) was used to 
assess cell viability after 72 hours post-transfection.
Quantitative real-time PCR (qRT-PCR). Total RNA was extracted from cells using miRNeasy kit 
(Qiagen, Toronto, Canada) according to the supplier protocols. 1 μ g RNA was reverse transcribed into com-
plementary DNA (cDNA) using Transcriptor First Strand cDNA Synthesis Kit (Roche, Laval, Canada) fol-
lowing instructions provided by the manufacturer. Real-time PCR reactions were prepared using LightCycler 
480 SYBR green I master kit (Roche), and were run on a LightCycler 480 instrument (Roche) according to the 
manufacturer’s recommendations. Triplicate PCR reactions were performed for each sample to ensure reliabil-
ity. Expression of KDM5D mRNA was normalized to the expression of the housekeeping gene GAPDH, and 
was reported as 2−ΔCt. All the primers were purchased from IDT (Coralville, IA, US). The sequences of primers 
were CGTGGAAGGACTCATGACCA (GAPDH forward), GCCATCACGCCACAGTTTC (GAPDH reverse), 
CGCAGCTTTGAAGAGCTAAG (KDM5D forward) and CAGCTGTGGAGTGTCCATCC (KDM5D reverse).
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